AstraZeneca has announced the official opening of its new South San Francisco location. Bay Area employees from Acerta Pharma, MedImmune, Pearl Therapeutics and AstraZeneca’s TIDE (Technology Innovation & Delivery Excellence) are now located at a single state-of-the-art facility in the Cove at Oyster Point, in the heart of the area’s vibrant biotechnology and technology community.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “The opening of our South San Francisco site is a milestone for AstraZeneca, enabling talent from four organizations to work side-by-side at the center of where biotechnology and high-tech industry intersects. This is a demonstration of our commitment to a strong and visible presence in California, our continued growth through science- and collaboration-led innovation, and our dedication to being a great place to work for current and future employees.”
Custom-designed to encourage collaboration and spark scientific innovation, the site’s facilities are equipped with cutting-edge open lab space and an office environment that incorporates AstraZeneca’s iWork philosophy, an activity-based working approach that embraces industry best practices.
Additional highlights of the purpose-built site include:
- Building and lab space that reflects AstraZeneca’s commitment to minimizing the environmental footprint of our products and processes
- Cutting-edge open and agile lab design, including windows into labs from public spaces to see science in action
- Design and architecture by HOK, a global design, architecture, engineering and planning firm with expertise in the design of sustainable biotech facilities
- Focus on health and safety for employees, with on-site pantries offering organic foods, adjustable desks and ergo dynamic chairs, treadmill-equipped team rooms, and an on-campus gym
Bahija Jallal, President of MedImmune and Executive Vice President of AstraZeneca, said: “Collaboration is at the core of our culture and a key driver of innovation. The opening of our new South San Francisco site brings together the best of both worlds — a shared drive across our employee base to advance great science and bring new treatments to patients, while providing an opportunity to tap into the Bay Area’s transformative biotech ecosystem, helping to foster great progress internally and externally.”